From the Journals

21-gene assay predicts survival in male and female breast cancer


 

FROM THE JOURNAL OF CLINICAL ONCOLOGY


Among the entire 21-gene assay sample, they found that men were significantly older than women at the time of diagnosis, at a mean age of 64.2 vs. 59.1 years (P less than .001).

Both men and women had infiltrating ductal carcinoma as the most common histology; the prevalence was slightly higher among men at 87.6% versus 81.3% for women.

The average recurrence score in men was 16.8 versus 17.0 in women, a difference that was not statistically significant. A majority of both men and women had RS scores below 18 (65.8% and 58.2%, respectively), although significantly more men than women had RS scores of 31 or higher (12.4% vs. 7.4%; P less than .001).

“This relative predominance of high RS results in men was encountered across age groups but was most prominent in men younger than 40 years of age,” the investigators wrote.

Pages

Recommended Reading

Breast cancer care delayed when patients have high deductibles
MDedge Hematology and Oncology
Age at time of breast cancer diagnosis differs by race/ethnicity
MDedge Hematology and Oncology
CECCY: Carvedilol didn’t curb cardiotoxicity in breast cancer patients
MDedge Hematology and Oncology
Gaps exist in receipt of clinically indicated genetic counseling after breast cancer diagnosis
MDedge Hematology and Oncology
Fulvestrant plus neratinib reversed treatment-acquired HER2 mutations in metastatic ER+ breast cancer
MDedge Hematology and Oncology
Accelerated breast irradiation advocated by ASTRO guideline
MDedge Hematology and Oncology
Late toxicities with PARP inhibitor plus RT in inflammatory breast cancer
MDedge Hematology and Oncology
HDAC inhibition may boost immune therapy efficacy in breast cancer
MDedge Hematology and Oncology
Over one-third report financial burden from breast cancer treatment
MDedge Hematology and Oncology
Think about breast cancer surveillance for transgender patients
MDedge Hematology and Oncology